SRGAP3

Overview

SRGAP3 (Slit-Robo Rho GTPase-Activating Protein 3) is a Rho GAP that couples SLIT-ROBO receptor signaling to actin cytoskeletal reorganization, influencing cell polarity and migration. Like SRGAP2, it acts in the SLIT-ROBO-SRGAP pathway controlling neural and epithelial cell movement. In adenoid cystic carcinoma (ACC), SRGAP3 mutation is part of a recurrently disrupted axon-guidance pathway hypothesized to facilitate perineural invasion.

Alterations observed in the corpus

SRGAP3 single-tumor somatic mutation detected in adenoid cystic carcinoma (ACC) of the salivary gland as part of a recurrently disrupted axon-guidance pathway (56% of tumors in the cohort) PMID:26862087

Cancer types (linked)

Adenoid cystic carcinoma (ACC): SRGAP3 mutation contributes to axon-guidance pathway disruption present in 56% of tumors PMID:26862087

Co-occurrence and mutual exclusivity

SRGAP3 mutation co-occurs with other axon-guidance pathway alterations (SLIT1, SRGAP2, SEMA3G, SEMA5A, PLXNA1, PLXNB1, PRKD1) in ACC PMID:26862087

Therapeutic relevance

Rho-pathway and axon-guidance pathway inhibition flagged as candidate therapeutic strategies for ACC; no functional or clinical data specific to SRGAP3 PMID:26862087

Open questions

Functional consequence of SRGAP3 mutation in ACC is uncharacterized PMID:26862087

Sources

PMID:26862087

This page was processed by crosslinker on 2026-05-14.